This Project Grant award, with Federal Grant Award ID R56CA286906, is funded by the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396). The award, totaling $164,500.00, supports research to identify targetable mechanisms underlying brain metastasis in patients with EGFR-mutant lung cancer.
The research, conducted by The Trustees of Columbia University in the City of New York, aims to 1) investigate how the protein S100A9 is epigenetically regulated to drive brain...
This Project Grant award of $699,125 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research to investigate the potential of targeting the enzyme 2-oxoglutarate dehydrogenase (OGDH) as a novel therapy for glioblastoma, the most common and deadly form of brain cancer. The research will build on the grantee's prior findings that OGDH is a critical driver of...
This federal Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $249,000.00 to the Trustees of the University of Pennsylvania to conduct research aimed at decoding the evolution and progression of glioma, an incurable brain cancer. The research plan involves developing novel single-cell technologies to concurrently profile the transcriptome, epigenome, and genome of glioma cells. This multi-dimensional profiling will help define how...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $682,596 to The University of Texas Southwestern Medical Center to study the metabolic mechanisms driving the progression of high-grade gliomas, a deadly type of brain cancer. The research aims to better understand how aberrant metabolite secretion by glioma cells impacts communication with surrounding neurons and contributes to tumor growth. This 5-year project will...
This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) will support a comprehensive, spatiotemporal analysis of cancer metastasis in small cell lung cancer (SCLC) at Columbia University. The key objectives are to: 1) Map the evolutionary dynamics and trajectories of SCLC metastasis using a novel lineage tracing mouse model; 2) Dissect the spatial context and cellular composition of the pro-metastatic tumor...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $193,144 to The Trustees of Columbia University in the City of New York to support a multidisciplinary postdoctoral training program focused on gastrointestinal (GI) cancers. The program aims to advance the understanding of GI cancers and reduce their morbidity and mortality by training the next generation of diverse GI cancer researchers. The 5-year award will support a...
This award provides funding for research into the relationship between inflammatory signaling in the leptomeninges (the membranes surrounding the brain and spinal cord) and the growth of leptomeningeal metastases, a lethal complication of cancer. The award is a $730,398 Project Grant funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396). The research is being conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,658 to New York University School of Medicine to conduct research on understanding the regulation of pyrimidine metabolism and its impact on cancer cell function and anti-tumor immunity. The research aims to:
Determine how pyrimidine overflow and disruption of the p53-dependent ribosome biogenesis checkpoint differentially affect cancer cells versus anti-cancer immune...
The National Cancer Institute awarded a $169,932 Project Grant under its Cancer Biology Research program (CFDA 93.396) to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division. The grant, with a project period from September 4, 2024 to July 31, 2029, will support the Proteomics and Macromolecular Crystallography Shared Resource (PMCSR) at the Herbert Irving Comprehensive Cancer Center (HICCC) in advancing proteomics technologies for cancer...
This federal Project Grant award of $898,209 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research conducted by the Dana-Farber Cancer Institute (DFCI) to better understand the molecular mechanisms underlying glioma formation and DNA damage response in brain tumors with mutations in the IDH1 gene. The research objectives include determining the response of a genetically engineered mouse model of IDH1-mutant grade 3 astrocytoma to IDH1 inhibitors and...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), provides $253,405 to The Trustees of Columbia University in the City of New York to investigate the role of purinergic signaling in glioma progression driven by neuronal activity.
The key products and services to be delivered under this award include in vitro and ex vivo imaging studies to determine the function of purinergic receptors in glioma cell calcium responses to neuronal activity, as well as in vivo two-photon imaging and wide-field optical mapping to assess the effects of neuronal activity, including seizures, on glioma cell calcium activity and progression. The project also aims to perturb purinergic signaling in glioma cells through genetic or pharmacological approaches to examine its role in neuron-glioma crosstalk, glioma cell proliferation, and glioma progression. This work will be conducted at Columbia University under the mentorship of the sponsor in collaboration with an interdisciplinary team of physician and basic scientists.